Marc Fishman

Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial

Joshua D. Lee, Edward V. Nunes, Patricia Novo et al. · The Lancet · 2017 · 681 citations · Full text

Opioid Epidemic, Comparative Effectiveness, Substance Abuse +10

Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders

Joshua D. Lee, Peter D. Friedmann, Timothy W. Kinlock et al. · New England Journal of Medicine · 2016 · 310 citations · Full text

HIV Risk Behaviors and Their Relationship to Posttraumatic Stress Disorder Among Women Prisoners

Heidi E. Hutton, Glenn J. Treisman, Wayne R. Hunt et al. · Psychiatric Services · 2001 · 153 citations

Randomized Controlled Trial of Osmotic-Release Methylphenidate With Cognitive-Behavioral Therapy in Adolescents With Attention-Deficit/Hyperactivity Disorder and Substance Use Disorders

Paula Riggs, Theresa Winhusen, Robert D. M. Davies et al. · Journal of the American Academy of Child & Adolescent Psychiatry · 2011 · 125 citations

Osmotic-release Methylphenidate, Adhd, Psychopathology +14

Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone

Edward V. Nunes, Michael Gordon, Peter D. Friedmann et al. · Journal of Substance Abuse Treatment · 2017 · 117 citations · Full text

Opioid Epidemic, Substance Use, Psychiatry +13